KODIAK SCIENCES INC

KODNASDAQ

🏆 #1697 by market capEarnings Aug 12US Equity

$43.33▲ $1.26 (+2.90%)

Live

1h▲ 0.7%

24h▲ 2.9%

7d▼ 0.7%

14d▲ 8.2%

30d▲ 5.3%

1y▲ 408.6%

🏦Market Cap

$2.71B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $42.85 – $44.13
52-Week Range: $7.69 – $47.84
Volume: $5.47B
Avg Volume: $7.01B
Shares Outstanding: 62.6M
Next Earnings: Oct 25, 2026

Fundamentals Snapshot

Annual Revenue: $335M
Last Q Revenue: $90M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-4.17
Dividend Yield: —

Why Investors Own KOD

✓High-growth profile — revenue up -7.3% YoY with expanding US Equity exposure.
✓Healthy economics — 60% gross margin and 12% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$335M▼ −6.1% YoY

Gross Margin (TTM)

59.5%▲ +1.7% YoY

Operating Income (TTM)

$83M▼ −6.1% YoY

Free Cash Flow (TTM)

$41M▼ −6.1% YoY

About KODIAK SCIENCES INC

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

🦦